Sunday, December 21, 2025 12/21/2025

Splenic Modulation of SHP-2 Activity as a Therapeutic Option for Systemic Lupus Erythematosus

Award Number: R21AR081535
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2025

Group Awards By:

View Award Description

Splenic Modulation of SHP-2 Activity as a Therapeutic Option for Systemic Lupus Erythematosus - PROJECT SUMMARY Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by a loss of tolerance to multiple endogenous antigens, for which there is no cure. Current therapeutic options for SLE patients involve a variety of non-specific immunosuppressive or anti-inflammatory agents that have significant associated side effects and are often inadequate. There is thus a great unmet need to develop curative therapies for this disease. In SLE, tissue injury is often mediated by aberrant expression of immunoregulatory signaling proteins. In particular, Src homology region 2 domain-containing phosphatase-2 (SHP-2) has been shown to enhance disease-active T cell proliferation and promote downstream cytokine production, each of which are innately tied to the pathophysiology of the disease. The importance of this phosphatase in the promotion of SLE has been further demonstrated by its inhibition, wherein systemic treatment normalized many of the symptoms of the disease concomitant with an extension of lifespan. Yet, SHP-2 is expressed throughout the body, thus the potential for off-target effects from systemic therapies is great. The spleen is the largest secondary lymphoid organ and an active regulator of the immune response, with a structure designed to increase the likelihood of rare interactions between cells, in particular cognate lymphocytes and antigen-presenting cells. While the spleen is not considered a target organ in SLE, it is an active site for autoantibody generation and the accumulation of pathogenic cells, including DNTCs, which are trafficked throughout the body to elicit the observed multi-organ damage. We thus hypothesize that the localization of therapeutics to the spleen, in particular modulators of SHP-2, may be sufficient to enable a systemic therapeutic effect. To accomplish this, we propose to utilize engineered senescent red blood cell mimetic nanohybrids to specifically deliver small molecule inhibitors or oligonucleotide-based therapeutics to the splenic milieu. If successful, the generated materials may potentiate the discovery of novel therapeutic options for the treatment of SLE with the capacity for increased specificity and decreased side effects.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	MASONIC MEDICAL RESEARCH LAB	2150 BLEECKER ST	UTICA	NY	13501	ONEIDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	1/23/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $189,926 )
2024	2024	MASONIC MEDICAL RESEARCH LAB	2150 BLEECKER ST	UTICA	NY	13501	ONEIDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	5/21/2024	NON-COMPETING CONTINUATION	$13,706
2024	2024	MASONIC MEDICAL RESEARCH LAB	2150 BLEECKER ST	UTICA	NY	13501	ONEIDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	3/8/2024	NON-COMPETING CONTINUATION	$176,220
														Subtotal = $189,926

Issue Date FY: 2023 ( Subtotal = $234,960 )
2023	2023	MASONIC MEDICAL RESEARCH LAB	2150 BLEECKER ST	UTICA	NY	13501	ONEIDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	2/15/2023	NEW	$234,960
														Subtotal = $234,960

Grand Total All Awards = $424,886

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Splenic Modulation of SHP-2 Activity as a Therapeutic Option for Systemic Lupus Erythematosus

Award Number: R21AR081535

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer